Rediet K.

Scientist Ii Scientist i, Early Discovery Oncology @Vividion Therapeutics, Inc.

Executed end-to-end assay development for multiple oncology targets—including candidate screening, hit validation, and SAR-driven optimization—to generate robust dose-response data and accurately determine IC50 values.• Validated compound on-target activity across multiple mechanisms of action by applying gene-editing strategies in disease-relevant cellular models.• Generated key multi-omics datasets (RNA-seq, ATAC-seq, CUT & RUN) to identify pharmacodynamic biomarkers supporting both in vitro and in vivo target engagement.• Drove two oncology programs to key milestone “GO” decisions, advancing them from early discovery and proof-of-concept studies into preclinical/clinical development pathways.